We found that 18F-AV-1451 PET imaging has superior diagnostic performance compared to CSF tau for AD in the dementia stage, but the 2 tau biomarker modalities have equal performance for prodromal AD. The gene discussed is MAPT; the disease is Alzheimer disease.